Buchumschlag

Pancreatic adenocarcinoma: long-term outcomes of adjuvant therapy in the ESPAC4 phase III Trial

Purpose - The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival for modified fluorouracil, folinic acid, irinotecan, an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Palmer, Daniel (VerfasserIn) , Jackson, Richard (VerfasserIn) , Springfeld, Christoph (VerfasserIn) , Ghaneh, Paula (VerfasserIn) , Rawcliffe, Charlotte (VerfasserIn) , Halloran, Christopher M. (VerfasserIn) , Faluyi, Olusola (VerfasserIn) , Cunningham, David (VerfasserIn) , Wadsley, Jonathan (VerfasserIn) , Darby, Suzanne (VerfasserIn) , Meyer, Tim (VerfasserIn) , Gillmore, Roopinder (VerfasserIn) , Lind, Pehr (VerfasserIn) , Glimelius, Bengt (VerfasserIn) , Falk, Stephen (VerfasserIn) , Ma, Yuk Ting (VerfasserIn) , Middleton, Gary William (VerfasserIn) , Cummins, Sebastian (VerfasserIn) , Ross, Paul J. (VerfasserIn) , Wasan, Harpreet (VerfasserIn) , McDonald, Alec (VerfasserIn) , Crosby, Tom (VerfasserIn) , Hammel, Pascal (VerfasserIn) , Borg, David (VerfasserIn) , Sothi, Sharmila (VerfasserIn) , Valle, Juan W. (VerfasserIn) , Mehrabi, Arianeb (VerfasserIn) , Bailey, Peter (VerfasserIn) , Tjaden, Christine (VerfasserIn) , Michalski, Christoph (VerfasserIn) , Hackert, Thilo (VerfasserIn) , Büchler, Markus W. (VerfasserIn) , Neoptolemos, John P. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2025
In: Journal of clinical oncology
Year: 2025, Jahrgang: 43, Heft: 10, Pages: 1240-1253
ISSN:1527-7755
DOI:10.1200/JCO.24.01118
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1200/JCO.24.01118
Verlag, kostenfrei, Volltext: https://ascopubs.org/doi/10.1200/JCO.24.01118
Volltext
Verfasserangaben:Daniel H. Palmer, Richard Jackson, Christoph Springfeld, Paula Ghaneh, Charlotte Rawcliffe, Christopher M. Halloran, Olusola Faluyi, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Pehr Lind, Bengt Glimelius, Stephen Falk, Yuk Ting Ma, Gary William Middleton, Sebastian Cummins, Paul J. Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Pascal Hammel, David Borg, Sharmila Sothi, Juan W. Valle, Arianeb Mehrabi, Peter Bailey, Christine Tjaden, Christoph Michalski, Thilo Hackert, Markus W. Büchler, and John P. Neoptolemos
Beschreibung
Zusammenfassung:Purpose - The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival for modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) than gemcitabine but had more restrictive eligibility criteria. Our aim was to analyze the ESPAC4 survival on long-term follow-up. - Methods - The OS of 732 ESPAC4 patients comparing 367 randomly assigned to gemcitabine and 365 to GemCap was previously reported after a median follow-up time of 43.2 months (95% CI, 39.7 to 45.5) and 458 deaths. Analysis was now carried out after a median follow-up of 104 months (101-108) and 566 deaths. - Results - The median OS was 29.5 months (27.5-32.1) for all patients, 28.4 months (25.2-32.0) in the gemcitabine group and 31.6 months (26.5-38.0) in the GemCap group (hazard ratio [HR], 0.83 [0.71 to 0.98]; P = .031). R0 patients given gemcitabine had a median survival of 32.2 months (27.9-41.6) compared with 49.9 months (39.0-82.3) for those given GemCap (HR, 0.63 [0.47 to 0.84]; P = .002). Lymph node-negative patients had significantly higher 5 year OS rates on GemCap (59% [49%-71%]) than gemcitabine (53% [42%-66%]; HR, 0.63 [0.41 to 0.98]; P = .04) but not those with positive lymph nodes (P = .225). The OS advantage for GemCap was retained in the PRODIGE24 subgroup of 193 (26.4%) ESPAC4 patients not eligible for PRODIGE24 with a median survival of 20.7 (16.2-27.3) months in patients allocated to gemcitabine compared with 25.9 (22.3-30.2) months for ineligible patients allocated to GemCap (HR, 0.71 [95% CI, 0.52 to 0.98]; χ2log-rank-1df = 4.31; P = .038). - Conclusion - GemCap is a standard option for patients not eligible for mFOLFIRINOX. Exploratory evidence suggests that GemCap may be particularly efficacious in R0 patients and also in lymph node-negative patients.
Beschreibung:Online veröffentlicht: 4. Dezember 2024
Gesehen am 14.11.2025
Beschreibung:Online Resource
ISSN:1527-7755
DOI:10.1200/JCO.24.01118

Ähnliche Einträge